The Exhibition Hall of Achievements of China’s Language Resources Protection Project Officially Opens 
HotelKey Announces Strategic Leadership Updates to Expand Global Footprint and Drive Operational Excellence 
Uniting for Shared Growth, Linking the World: 2026 FHC Future Health Industry Conference Successfully Held in Hangzhou Restore Hyper Wellness Appoints Emma Nasif as Chief Compliance Officer
Fastest-growing retail wellness brand expands in-house legal counsel AUSTIN, Texas–(BUSINESS WIRE)–Restore Hyper Wellness (Restore), a…
Elements Receives $5 Million in Funding from Flyover Capital
Seed round extension will further Elements’ efforts to grow its client base and provide more…
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
– HAVs observed to provide long-term perfusion to patients with critical limb ischemia – 3D…
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (the “Company,” “Finch,”…
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company…
Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates
– Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release…
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum…
Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions
Pricing Provides VENDAJETM Reimbursement in All MAC Regions POMPANO BEACH, FLORIDA., Jan. 24, 2023 (GLOBE…
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
iSpecimen Appoints Eric Langlois as Chief Revenue Officer
Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company’s…
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF)…
Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company’s Development of Monoclonal Antibody Therapeutics for Monkeypox and Smallpox
Data Represent Research and Development Work Being Conducted at Tonix’s Infectious Disease R&D Center (RDC)…
First Wave BioPharma to Present at Sequire Biotechnology Conference
BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First…
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase…
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage…
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA • FDA…